Renovis Initiates Phase Ia Study With Investigational Medicine for MS

Renovis has initiated a Phase Ia clinical trial for REN-850, an investigational oral small molecule that is being targeted for the treatment of multiple sclerosis (MS).

The objective of this trial is to assess the safety, tolerability and pharmacokinetics of escalating single doses of REN-850 in healthy volunteers. Approximately 45 subjects are planned to participate in the study.

REN-850 acts by inhibiting leukocyte trafficking, and preclinical studies have shown that REN-850 modulates the cell migration driven by multiple chemokine receptors. These studies have also shown that oral administration of REN-850 significantly reduces severity of outcomes in multiple in vivo models of MS and rheumatoid arthritis.